📊 LAB Key Takeaways
Is LAB a Good Investment? Thesis Analysis
Standard Biotools is experiencing severe operational distress with -$87.8% net margins and -$82.6M free cash flow burn, despite maintaining a strong balance sheet with $120.9M cash and minimal debt. Revenue is declining YoY at -6.2%, indicating market challenges, while the company has only ~1.5 years of cash runway at current burn rates unless operations improve materially.
Why Buy LAB? Key Strengths
- Minimal leverage with $299K long-term debt and 0.00x Debt/Equity ratio
- Strong liquidity position with 4.19x current ratio and $120.9M cash reserves
- Healthy 49.9% gross margin demonstrates underlying product viability and pricing power
LAB Investment Risks to Consider
- Catastrophic operating losses of -$110.2M (-129.2% operating margin) on only $85.3M revenue indicates fundamental business model failure
- Unsustainable free cash flow burn of -$82.6M annually with negative operating cash flow of -$74.3M threatening company survival
- Declining revenue trend (-6.2% YoY) combined with negative profitability suggests market share loss and inability to achieve scale
Key Metrics to Watch
- Revenue stabilization and return to growth
- Operating cash flow inflection from -$74.3M toward positive territory
- Operating margin improvement and path to profitability
LAB Financial Metrics
💡 AI Analyst Insight
Strong liquidity with a 4.19x current ratio provides a solid financial cushion.
LAB Profitability Ratios
LAB vs Default Sector
How STANDARD BIOTOOLS INC. compares to Default sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is LAB Overvalued or Undervalued?
Based on fundamental analysis, STANDARD BIOTOOLS INC. has mixed fundamental signals relative to the Default sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
LAB Balance Sheet & Liquidity
LAB 5-Year Financial Trend & Growth Analysis
5-Year Trend Summary: STANDARD BIOTOOLS INC.'s revenue has declined by 23% over the 5-year period, indicating business contraction. The most recent EPS of $-0.94 indicates the company is currently unprofitable.
LAB Growth Metrics (YoY)
LAB Quarterly Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2025 | $19.6M | -$26.0M | $-0.07 |
| Q2 2025 | $21.8M | -$26.0M | $-0.09 |
| Q1 2025 | $40.8M | -$26.0M | $-0.07 |
| Q3 2024 | $25.1M | -$16.8M | $-0.07 |
| Q2 2024 | $27.7M | -$16.8M | $-0.12 |
| Q3 2023 | $25.4M | -$16.8M | $-0.27 |
| Q2 2023 | $18.8M | -$16.8M | $-0.22 |
| Q1 2023 | $25.1M | -$16.8M | $-0.21 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
LAB Capital Allocation
LAB SEC 10-K & 10-Q Filing Analysis
Access official SEC EDGAR filings for STANDARD BIOTOOLS INC. (CIK: 0001162194)
📋 Recent SEC Filings
❓ Frequently Asked Questions about LAB
What is the AI rating for LAB?
STANDARD BIOTOOLS INC. (LAB) has an AI rating of STRONG SELL with 88% confidence, based on fundamental analysis of SEC EDGAR filings.
What are LAB's key strengths?
Claude: Minimal leverage with $299K long-term debt and 0.00x Debt/Equity ratio. Strong liquidity position with 4.19x current ratio and $120.9M cash reserves.
What are the risks of investing in LAB?
Claude: Catastrophic operating losses of -$110.2M (-129.2% operating margin) on only $85.3M revenue indicates fundamental business model failure. Unsustainable free cash flow burn of -$82.6M annually with negative operating cash flow of -$74.3M threatening company survival.
What is LAB's revenue and growth?
STANDARD BIOTOOLS INC. reported revenue of $85.3M.
Does LAB pay dividends?
STANDARD BIOTOOLS INC. does not currently pay dividends.
Where can I find LAB SEC filings?
Official SEC filings for STANDARD BIOTOOLS INC. (CIK: 0001162194) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is LAB's EPS?
STANDARD BIOTOOLS INC. has a diluted EPS of $-0.20.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is LAB a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, STANDARD BIOTOOLS INC. has a STRONG SELL rating with 88% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is LAB stock overvalued or undervalued?
Valuation metrics for LAB: ROE of -17.7% (sector avg: 15%), net margin of -87.8% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy LAB stock in 2026?
Our dual AI analysis gives STANDARD BIOTOOLS INC. a combined STRONG SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is LAB's free cash flow?
STANDARD BIOTOOLS INC.'s operating cash flow is $-74.3M, with capital expenditures of $8.3M. FCF margin is -96.9%.
How does LAB compare to other Default stocks?
Vs Default sector averages: Net margin -87.8% (avg: 12%), ROE -17.7% (avg: 15%), current ratio 4.19 (avg: 1.8).